Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer

Abstract To determine the prognostic value of the timing of circulating breast tumour cell measurement during treatment, peripheral blood from 164 patients with breast disease was collected. Circulating tumour cells (CTCs) were enriched by using immunomagnetic nanospheres (IMNs) and were identified...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuyun Pang, Hanjun Li, Shu Xu, Liying Feng, Xueping Ma, Yanan Chu, Bingjie Zou, Shaohua Wang, Guohua Zhou
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/eb6c969eb23542aba07c636a853962c6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb6c969eb23542aba07c636a853962c6
record_format	dspace
spelling	oai:doaj.org-article:eb6c969eb23542aba07c636a853962c62021-12-02T16:32:02ZCirculating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer10.1038/s41598-021-92876-82045-2322https://doaj.org/article/eb6c969eb23542aba07c636a853962c62021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92876-8https://doaj.org/toc/2045-2322Abstract To determine the prognostic value of the timing of circulating breast tumour cell measurement during treatment, peripheral blood from 164 patients with breast disease was collected. Circulating tumour cells (CTCs) were enriched by using immunomagnetic nanospheres (IMNs) and were identified by using immunofluorescent staining. The CTC shows nuclear-positive, EpCAM-positive, CK19-positive, and CD45-negative. Patients with CTC positivity (> 19/7.5 mL blood) had shorter progression-free survival (PFS) and overall survival (OS) than those with negative results (≤ 19/7.5 mL blood) at baseline. Surgery caused an increase in the number and prevalence of CTCs, and the effect disappeared on day 14 after surgery. During adjuvant chemotherapy, CTCs detected before therapy was only correlated with PFS; however, CTCs at the end of adjuvant chemotherapy were correlated with both PFS and OS. The PFS and OS of the CTC-positive group were significantly shorter than those of the CTC-negative group at the end-point follow-up visit. The prognostic value of CTCs at different measurement time points was demonstrated during breast cancer treatment. Surgery and chemotherapy affected the prevalence of CTCs, leading to different prognostic relevance of CTCs at different treatment stages. CTCs detected at baseline or in the late phase of treatment are preferable for prognosis.Shuyun PangHanjun LiShu XuLiying FengXueping MaYanan ChuBingjie ZouShaohua WangGuohua ZhouNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shuyun Pang Hanjun Li Shu Xu Liying Feng Xueping Ma Yanan Chu Bingjie Zou Shaohua Wang Guohua Zhou Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
description	Abstract To determine the prognostic value of the timing of circulating breast tumour cell measurement during treatment, peripheral blood from 164 patients with breast disease was collected. Circulating tumour cells (CTCs) were enriched by using immunomagnetic nanospheres (IMNs) and were identified by using immunofluorescent staining. The CTC shows nuclear-positive, EpCAM-positive, CK19-positive, and CD45-negative. Patients with CTC positivity (> 19/7.5 mL blood) had shorter progression-free survival (PFS) and overall survival (OS) than those with negative results (≤ 19/7.5 mL blood) at baseline. Surgery caused an increase in the number and prevalence of CTCs, and the effect disappeared on day 14 after surgery. During adjuvant chemotherapy, CTCs detected before therapy was only correlated with PFS; however, CTCs at the end of adjuvant chemotherapy were correlated with both PFS and OS. The PFS and OS of the CTC-positive group were significantly shorter than those of the CTC-negative group at the end-point follow-up visit. The prognostic value of CTCs at different measurement time points was demonstrated during breast cancer treatment. Surgery and chemotherapy affected the prevalence of CTCs, leading to different prognostic relevance of CTCs at different treatment stages. CTCs detected at baseline or in the late phase of treatment are preferable for prognosis.
format	article
author	Shuyun Pang Hanjun Li Shu Xu Liying Feng Xueping Ma Yanan Chu Bingjie Zou Shaohua Wang Guohua Zhou
author_facet	Shuyun Pang Hanjun Li Shu Xu Liying Feng Xueping Ma Yanan Chu Bingjie Zou Shaohua Wang Guohua Zhou
author_sort	Shuyun Pang
title	Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
title_short	Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
title_full	Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
title_fullStr	Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
title_full_unstemmed	Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
title_sort	circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/eb6c969eb23542aba07c636a853962c6
work_keys_str_mv	AT shuyunpang circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT hanjunli circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT shuxu circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT liyingfeng circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT xuepingma circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT yananchu circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT bingjiezou circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT shaohuawang circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer AT guohuazhou circulatingtumourcellsatbaselineandlatephaseoftreatmentprovideprognosticvalueinbreastcancer
_version_	1718383844089921536

Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer

Ejemplares similares